Q-omics provides the consensus-scored HNMT profile across patient tissues and cancer cell-line models. HNMT expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HNMT is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, HNMT protein abundance shows 28,827 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, KICH, and LSCC as cancer lineages where HNMT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNMT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNMT survival associations across molecular data types. HNMT RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNMT RNA expression–survival associations across cancer types. High HNMT expression shows favorable associations in KIRC, UVM, UCEC, BLCA, SARC and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HNMT RNA expression.
This table summarizes HNMT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in KICH for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for HNMT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNMT shows lower tumor expression in KICH, KIRP, UCEC, LUSC, HNSC and BRCA. The KICH box plot shows higher HNMT RNA expression in normal versus tumor tissue (log2 FC = −2.755, t-test p < 0.001).
This table shows molecular features associated with HNMT in patient tissues and cancer cell lines. In patient samples, HNMT shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, HNMT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
